Abstract
BackgroundLow-grade glioma is grade I-II glioma. Immunotherapy is a promising way of tumor killing. Research on immune molecular mechanisms in low-grade gliomas and discovery of new immune checkpoints for low-grade gliomas are of great importance.MethodsGene sequencing data and clinical data of low-grade glioma were downloaded from TCGA database. Prognosis related lncRNAs were identified by Cox regression and their possible functions were found by gene enrichment set analysis.ResultsA total of 529 low-grade glioma samples and 5 non-tumor brain tissue samples are obtained from the TCGA database. Two hundred forty-seven immune-associated lncRNAs are screened. Cox regression showed that 16 immune-related lncRNAs are associated with low-grade glioma prognosis, and 7 lncRNAs are independent risk factors. Gene set enrichment analysis suggests that these molecules are enriched in extracellular region, sequence-specific DNA binding, neuropeptide signaling pathway, transcriptional misregulation in cancer, cytokine-cytokine receptor interaction, protein digestion and absorption, chemokine signaling pathway, etc.ConclusionThe identification of immune-related lncRNA may provide new targets for the research of the molecular mechanisms and treatment of low-grade glioma.
Highlights
This study identified immune-related Long non-coding RNA (lncRNA) in low-grade gliomas and explored the relationship between these immune-related lncRNAs and the prognosis of low-grade gliomas
Expressed lncRNAs in low-grade glioma A total of 529 low-grade glioma samples and 5 nontumor brain tissue samples were obtained from the TCGA database
By contrasting the tumor samples and normal samples, 717 glioblastomas differentially expressed lncRNAs were screened with the threshold of |log2FC| > 2 and false discovery rate (FDR) < 0.05
Summary
Immunotherapy is a promising way of tumor killing. Research on immune molecular mechanisms in low-grade gliomas and discovery of new immune checkpoints for low-grade gliomas are of great importance. Low-grade glioma is grade I-II glioma, the main components of which are oligodendroglioma and astrocytoma. The current treatment of low-grade gliomas still tends to be based on surgically based comprehensive treatment [2, 3]. Immunotherapy is a new way of killing tumors. Glioma immunotherapy has a long history, the effect is unsatisfactory [6]. The study of immune molecular mechanisms for lowgrade gliomas and the discovery of new immune checkpoints are important for the treatment of low-
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
